[go: up one dir, main page]

ES2661132T3 - Adenovirus oncolíticos armados con genes heterólogos - Google Patents

Adenovirus oncolíticos armados con genes heterólogos Download PDF

Info

Publication number
ES2661132T3
ES2661132T3 ES14799117T ES14799117T ES2661132T3 ES 2661132 T3 ES2661132 T3 ES 2661132T3 ES 14799117 T ES14799117 T ES 14799117T ES 14799117 T ES14799117 T ES 14799117T ES 2661132 T3 ES2661132 T3 ES 2661132T3
Authority
ES
Spain
Prior art keywords
sequence
group
link
heterologous genes
itr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14799117T
Other languages
English (en)
Inventor
Brian Robert Champion
Alice Claire Noel BROWN
Kerry David Fisher
Tamara NICOLSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akamis Bio Ltd
Original Assignee
Psioxus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1318880.0A external-priority patent/GB201318880D0/en
Priority claimed from GB201318885A external-priority patent/GB201318885D0/en
Priority claimed from GBGB1322851.5A external-priority patent/GB201322851D0/en
Priority claimed from GB201401159A external-priority patent/GB201401159D0/en
Priority claimed from GB201406470A external-priority patent/GB201406470D0/en
Application filed by Psioxus Therapeutics Ltd filed Critical Psioxus Therapeutics Ltd
Application granted granted Critical
Publication of ES2661132T3 publication Critical patent/ES2661132T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un adenovirus oncolítico del grupo B competente en replicación que comprende una secuencia de fórmula (I): 5'ITR-B1-BA-B2-BX-BB-BY-B3-3'ITR en donde: B1 comprende: E1A, E1B o E1A-E1B; BA comprende: E2B-L1-L2-L3-E2A-L4; B2 es un enlace o comprende: E3; BX es un enlace o una secuencia de ADN que comprende: un sitio de restricción, uno o más transgenes o ambos; BB comprende L5; BY comprende un casete transgénico que comprende un transgén y una secuencia aceptora de empalme; y B3 es un enlace o comprende: E4, en el que el casete transgénico está bajo el control de un promotor endógeno seleccionado del grupo que consiste en E4 y el promotor tardío principal, y en el que el casete transgénico comprende un gen terapéutico que codifica un material seleccionado del grupo que consiste en una secuencia RNAi, una proteína, un anticuerpo o fragmento de unión del mismo, una quimioquina, una citocina, un inmunomodulador y una enzima.
ES14799117T 2013-10-25 2014-10-24 Adenovirus oncolíticos armados con genes heterólogos Active ES2661132T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB1318880.0A GB201318880D0 (en) 2013-10-25 2013-10-25 Adenovirus
GB201318885A GB201318885D0 (en) 2013-10-25 2013-10-25 Adenovirus
GBGB1322851.5A GB201322851D0 (en) 2013-12-23 2013-12-23 Method
GB201401159A GB201401159D0 (en) 2014-01-23 2014-01-23 Adenovirus
GB201406470A GB201406470D0 (en) 2014-04-10 2014-04-10 Virus
PCT/EP2014/072919 WO2015059303A1 (en) 2013-10-25 2014-10-24 Oncolytic adenoviruses armed with heterologous genes

Publications (1)

Publication Number Publication Date
ES2661132T3 true ES2661132T3 (es) 2018-03-27

Family

ID=51900851

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14799117T Active ES2661132T3 (es) 2013-10-25 2014-10-24 Adenovirus oncolíticos armados con genes heterólogos

Country Status (31)

Country Link
US (4) US9987314B2 (es)
EP (3) EP3831398A1 (es)
KR (1) KR102272932B1 (es)
CN (2) CN114457044A (es)
AU (1) AU2014338864C1 (es)
CA (2) CA2927968C (es)
CL (1) CL2016000959A1 (es)
CY (1) CY1119955T1 (es)
DK (1) DK3021859T3 (es)
EA (1) EA036414B1 (es)
ES (1) ES2661132T3 (es)
HR (1) HRP20180317T1 (es)
HU (1) HUE035875T2 (es)
IL (2) IL244944B (es)
LT (1) LT3021859T (es)
MX (1) MX373835B (es)
MY (1) MY175614A (es)
NO (1) NO3021859T3 (es)
NZ (1) NZ718931A (es)
PE (1) PE20160951A1 (es)
PH (1) PH12016500759B1 (es)
PL (1) PL3021859T3 (es)
PT (1) PT3021859T (es)
RS (1) RS57043B1 (es)
SA (1) SA516371011B1 (es)
SG (2) SG10201804030WA (es)
SI (1) SI3021859T1 (es)
SM (1) SMT201800130T1 (es)
TR (1) TR201802728T4 (es)
WO (1) WO2015059303A1 (es)
ZA (1) ZA201603646B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015030881A2 (pt) 2013-06-14 2017-10-24 Psioxus Theraupeutics Ltd “regime de dosagem e formulações para adenovírus de tipo b”
EP3831398A1 (en) 2013-10-25 2021-06-09 PsiOxus Therapeutics Limited Oncolytic adenoviruses armed with heterologous genes
GB201406608D0 (en) * 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
GB201510197D0 (en) 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
SG11201701502VA (en) 2014-08-27 2017-03-30 Psioxus Therapeutics Ltd A process for the production of adenovirus
US10973914B2 (en) 2015-02-20 2021-04-13 Ohio State Innovation Foundation Bivalent antibody directed against NKG2D and tumor associated antigens
JP6879932B2 (ja) 2015-04-06 2021-06-02 サイトイミューン セラピューティクス， インコーポレイテッドＣｙｔｏｉｍｍｕｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｌｃ 神経膠芽腫のためのｅｇｆｒ指向ｃａｒ療法
KR20180118249A (ko) * 2015-04-30 2018-10-30 싸이오서스 테라퓨틱스 엘티디. B7 단백질을 암호화하는 종양세포붕괴 아데노바이러스
AU2016369485B2 (en) * 2015-12-17 2024-02-01 Akamis Bio Limited Group B adenovirus encoding an anti-TCR-complex antibody or fragment
CA3010987A1 (en) 2016-01-08 2017-07-13 Replimune Limited Oncolytic herpes simplex virus type 1 strain
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
GB201713765D0 (en) * 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
CA3033267A1 (en) * 2016-08-29 2018-03-08 Psioxus Therapeutics Limited Adenovirus armed with bispecific t cell engager (bite)
WO2018083258A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083257A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083259A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
GB201700350D0 (en) * 2017-01-09 2017-02-22 Replimune Ltd Altered virus
WO2018170763A1 (zh) * 2017-03-22 2018-09-27 深圳市博奥康生物科技有限公司 ILA 基因的 RNAi 表达载体及其构建方法和应用
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
CN118308311A (zh) * 2017-06-01 2024-07-09 阿卡米斯生物公司 溶瘤病毒和方法
JP7403444B2 (ja) * 2017-10-20 2023-12-22 エフ． ホフマン－ラ ロシュ アーゲー 抗体の複写保護措置
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
KR20210044774A (ko) * 2018-07-04 2021-04-23 사이토이뮨 테라퓨틱스 인코퍼레이티드 Flt3, pd-1 및/또는 pd-l1을 표적으로 하는 면역요법을 위한 조성물 및 방법
JP7340591B2 (ja) 2018-07-11 2023-09-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
WO2020052551A1 (en) * 2018-09-10 2020-03-19 Genesail Biotech (Shanghai) Co. Ltd. A modified oncolytic virus, composition and use thereof
EP3927833A4 (en) * 2019-02-21 2022-11-30 Unleash Immuno Oncolytics, Inc. ONCOLYTIC ADENOVIRAL VECTOR AND METHODS OF USE
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
CA3176660A1 (en) 2019-02-27 2020-09-03 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
GB201909081D0 (en) 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
IL292836A (en) 2019-11-12 2022-07-01 Actym Therapeutics Inc Platforms for administering bacteria that stimulate the immune system and their use for administering therapeutic products
KR20210118760A (ko) * 2020-03-23 2021-10-01 (주)큐리진 AR 및 mTOR를 이중 특이적으로 표적하는 핵산분자를 포함하는 항암바이러스
KR20210118757A (ko) * 2020-03-23 2021-10-01 (주)큐리진 STAT3 및 mTOR를 이중 특이적으로 표적하는 핵산서열을 포함한 항암 바이러스
KR102601875B1 (ko) * 2020-03-25 2023-11-14 (주)큐리진 면역 회피성 항종양 아데노바이러스
WO2021202532A1 (en) * 2020-03-31 2021-10-07 Ultragenyx Pharmaceutical Inc. Gene therapy for treating propionic acidemia
AU2021324883A1 (en) 2020-08-12 2023-03-23 Actym Therapeutics, Inc. Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
AU2021410765A1 (en) * 2020-12-22 2023-07-13 Ensoma, Inc. Adenoviral gene therapy vectors
WO2022135357A1 (en) * 2020-12-22 2022-06-30 Sunshine Lake Pharma Co., Ltd. A hIL7/hCCL19 DOUBLE GENE RECOMBINANT ONCOLYTIC VIRUS AND ITS PREPARATION METHOD AND USE
GB202102049D0 (en) 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses
EP4404947A4 (en) 2021-09-23 2025-12-10 Sagittarius Bio Inc Adenovirus and Methods of Using Adenovirus
EP4429682A2 (en) 2021-11-09 2024-09-18 Actym Therapeutics, Inc. Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment
EP4486787A1 (en) * 2022-03-03 2025-01-08 Board of Regents, The University of Texas System Anti-cd19 and anti-cd79b chimeric antigen receptors and methods of use thereof
CN116836283B (zh) * 2022-05-17 2024-05-07 苏州万灏生物科技有限公司 具有多种免疫调节因子的增强型溶瘤病毒及其制备方法和应用
AU2024277678A1 (en) 2023-05-25 2025-11-27 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170269A3 (en) 1984-08-02 1987-09-23 Kao Corporation Medicated cosmetic compositions
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
BR9405507A (pt) 1993-07-13 1999-05-25 Rhone Poulenc Rorer Sa Adenovirus recombinante defeituoso linhagem celular e composição farmaceutica
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
FR2730504B1 (fr) * 1995-02-13 1997-03-28 Rhone Poulenc Rorer Sa Procede de preparation de genomes d'adenovirus recombinants
DE19648650C2 (de) 1996-01-29 1998-07-02 Schering Ag Puffersysteme und deren Verwendung zur Stabilisierung pharmazeutischer Zubereitung
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US5877011A (en) 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
CN1242051A (zh) 1996-12-31 2000-01-19 昂尼克斯药物公司 用于肿瘤治疗和预防的致细胞病变病毒
DE69838510T2 (de) 1997-02-20 2008-07-03 Johns Hopkins University School Of Medicine Mutationen in atp-abhängigen transpositionsproteinen die die zielortspezifität reduzieren
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
AU9603898A (en) 1997-10-09 1999-05-03 Pro-Virus, Inc. Treatment of neoplasms with viruses
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
US20020019051A1 (en) 1998-05-27 2002-02-14 Monika Lusky Chimeric adenoviral vectors
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
CN1110553C (zh) 1998-07-15 2003-06-04 杭州赛狮生物技术开发有限公司 基因工程腺病毒及其用途
CN1257286C (zh) * 1998-08-27 2006-05-24 森泰莱昂公司 用于递送异源基因的定向腺病毒载体
AU767975B2 (en) 1998-09-11 2003-11-27 Genvec, Inc. Alternatively targeted adenovirus
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
JP4409097B2 (ja) 1998-12-09 2010-02-03 アメリカ合衆国 複数の共刺激分子を発現する組換えベクターおよびその利用
DE60029195T2 (de) 1999-02-22 2007-06-28 Transgene S.A. Verfahren zur Gewinnung von purifizierter Virenzusammensetzung
PL351553A1 (en) 1999-04-09 2003-05-05 Aventis Pharma Sa Composition intended to preserve contagious adenoviruses of recombination type
PT1816205E (pt) 1999-05-17 2011-11-15 Crucell Holland Bv Adenovírus recombinante baseado no serótipo 48 (ad48)
ATE291633T1 (de) 1999-06-01 2005-04-15 Univ Washington Rekombinante adenovirale vektoren, die chimäre fiberproteine exprimieren, für die zellspezifische infektion und genomische integration
JP4827353B2 (ja) 1999-08-09 2011-11-30 ターゲティッド ジェネティクス コーポレイション 鎖内塩基対を形成するような配列の設計による、組換えウイルスベクターからの一本鎖の異種ヌクレオチド配列の発現の増大
US7396679B2 (en) 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
AU2695101A (en) 2000-01-21 2001-07-31 Biovex Ltd Virus strains
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
EP1301612A2 (en) 2000-05-31 2003-04-16 Genvec, Inc. Method and composition for targeting an adenoviral vector
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
JP2004500863A (ja) 2000-06-06 2004-01-15 ブリストル−マイヤーズ　スクイブ　カンパニー 免疫調節に有用なｂ７関連核酸およびポリペプチド
WO2002053759A1 (en) 2001-01-04 2002-07-11 Wadell Goeran Viral vector for gene therapy
US20050175589A1 (en) 2001-07-13 2005-08-11 Btg International Limited Anti-neoplastic viral agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1327688A1 (en) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
CA2474777A1 (en) 2002-02-01 2003-08-07 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with pods
AU2003223775A1 (en) 2002-04-30 2003-11-17 Duke University Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
PT1570267E (pt) 2002-12-03 2012-01-03 Ucb Pharma Sa Ensaio para a identificação de células produtoras de anticorpos
US20040167088A1 (en) 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo
WO2004087930A1 (en) 2003-03-28 2004-10-14 Saint Louis University Adenovirus replication-competent vectors expressing trail
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US7989594B2 (en) 2003-07-01 2011-08-02 Celltech R & D Limited Modified antibody fab fragments
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
EP1646717A4 (en) 2003-07-18 2006-12-20 Onyx Pharma Inc ADENOVIRAL VECTORS OF SUB-GROUP B FOR THE TREATMENT OF DISEASES
US20050186178A1 (en) 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
KR20120125634A (ko) 2003-10-16 2012-11-16 마이크로메트 에이지 다중특이적 탈면역화된 ｃｄ3-바인더
WO2005086922A2 (en) * 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
US20080292592A1 (en) 2004-04-30 2008-11-27 Sunil Chada Oncolytic Adenovirus Armed with Therapeutic Genes
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
ATE491799T1 (de) 2004-05-26 2011-01-15 Bayer Schering Pharma Ag Chimäre adenoviren zur verwendung in der krebsbehandlung
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
US20060292682A1 (en) 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
JP2008511336A (ja) 2004-09-01 2008-04-17 アメリカ合衆国 免疫原性が増加したアデノウイルスベクターをインビボで用いる方法
US7550296B2 (en) 2004-12-01 2009-06-23 Bayer Schering Pharma Ag Generation of replication competent viruses for therapeutic use
US20060205080A1 (en) 2005-03-01 2006-09-14 David Frey Formulations for therapeutic viruses having enhanced storage stability
US8765146B2 (en) 2005-08-31 2014-07-01 Genvec, Inc. Adenoviral vector-based malaria vaccines
CN1961961B (zh) 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
DE102005055128B4 (de) 2005-11-15 2015-04-02 Universität Rostock Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
ES2304281B1 (es) 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
JP5448840B2 (ja) 2006-12-22 2014-03-19 プシオクサス・セラピューティクス・リミテッド 腫瘍退縮アデノウイルスの作出およびその使用
CA2700714C (en) 2007-09-26 2018-09-11 Ucb Pharma S.A. Dual specificity antibody fusions
WO2009097443A2 (en) 2008-01-29 2009-08-06 Remedy Pharmaceuticals, Inc. Liquid formulations of compounds active at sulfonylurea receptors
CN102695520A (zh) 2008-05-27 2012-09-26 昂科利蒂克斯生物科技公司 调节间隙压力与溶瘤病毒的递送和分布
PT2334705T (pt) 2008-09-26 2017-03-22 Ucb Biopharma Sprl Produtos biológicos
US20120034228A1 (en) 2008-10-01 2012-02-09 Micromet Ag CROSS-SPECIES-SPECIFIC PSCAxCD3, CD19xCD3, C-METxCD3, ENDOSIALINxCD3, EPCAMxCD3, IGF-1RxCD3 OR FAPALPHAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
US20100297072A1 (en) 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
WO2011043719A1 (en) 2009-10-05 2011-04-14 Ya-Fang Mei Replicating viral vectors for gene therapy
JP5981916B2 (ja) 2010-08-16 2016-09-07 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの構築方法
CN103221544A (zh) 2010-09-24 2013-07-24 昂克斯治疗有限公司 编码单克隆抗-ctla-4抗体的溶瘤腺病毒载体
ES2857734T3 (es) 2011-08-23 2021-09-29 Roche Glycart Ag Moléculas de unión a antígeno activadoras de linfocitos T biespecíficas
US20140316369A1 (en) 2011-11-14 2014-10-23 Regenerative Sciences, Llc Suspended particle delivery systems and methods
CN102586327B (zh) 2012-01-18 2013-09-11 陕西师范大学 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用
SG11201406592QA (en) 2012-05-04 2014-11-27 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
JP2016512199A (ja) 2013-03-05 2016-04-25 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 腫瘍溶解性ウイルス
WO2015040234A1 (en) 2013-09-23 2015-03-26 Crucell Holland B.V. Adenovirus formulations
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
GB201318793D0 (en) 2013-10-24 2013-12-11 Plaquetec Ltd Vascular Biomarkers
EP3831398A1 (en) 2013-10-25 2021-06-09 PsiOxus Therapeutics Limited Oncolytic adenoviruses armed with heterologous genes
CA2931322A1 (en) 2013-11-22 2015-05-28 Dnatrix, Inc. Adenovirus expressing immune cell stimulatory receptor agonist(s)
WO2015153912A1 (en) 2014-04-03 2015-10-08 Igm Biosciences, Inc. Modified j-chain
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
SG11201701502VA (en) 2014-08-27 2017-03-30 Psioxus Therapeutics Ltd A process for the production of adenovirus
GB201503500D0 (en) 2015-03-02 2015-04-15 Ucl Business Plc Cell
CN107406859A (zh) 2015-03-17 2017-11-28 倾斜生物医疗公司 编码双特异性抗体的溶瘤腺病毒及与其相关的方法和用途
KR20180118249A (ko) 2015-04-30 2018-10-30 싸이오서스 테라퓨틱스 엘티디. B7 단백질을 암호화하는 종양세포붕괴 아데노바이러스
AU2016369485B2 (en) 2015-12-17 2024-02-01 Akamis Bio Limited Group B adenovirus encoding an anti-TCR-complex antibody or fragment
CA3033267A1 (en) 2016-08-29 2018-03-08 Psioxus Therapeutics Limited Adenovirus armed with bispecific t cell engager (bite)
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
EP3872180A1 (en) 2016-10-20 2021-09-01 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083259A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation

Also Published As

Publication number Publication date
CA3183645A1 (en) 2015-04-30
PL3021859T3 (pl) 2018-06-29
CN108064159B (zh) 2021-12-10
IL244944B (en) 2019-09-26
EP3831398A1 (en) 2021-06-09
SI3021859T1 (en) 2018-04-30
EP3021859B1 (en) 2017-11-29
MY175614A (en) 2020-07-01
PT3021859T (pt) 2018-03-09
KR102272932B1 (ko) 2021-07-05
CY1119955T1 (el) 2018-12-12
IL269304B (en) 2020-06-30
DK3021859T3 (en) 2018-03-05
US11439678B2 (en) 2022-09-13
CL2016000959A1 (es) 2016-12-02
AU2014338864C1 (en) 2020-07-16
AU2014338864B2 (en) 2019-11-21
SG10201804030WA (en) 2018-07-30
IL244944A0 (en) 2016-05-31
SA516371011B1 (ar) 2020-08-13
SMT201800130T1 (it) 2018-05-02
US11938159B2 (en) 2024-03-26
CA2927968A1 (en) 2015-04-30
PH12016500759A1 (en) 2016-05-30
RS57043B1 (sr) 2018-05-31
US20240325472A1 (en) 2024-10-03
PH12016500759B1 (en) 2016-05-30
HRP20180317T1 (hr) 2018-07-13
EA036414B1 (ru) 2020-11-09
US20210187047A1 (en) 2021-06-24
EP3372236A1 (en) 2018-09-12
IL269304A (en) 2019-11-28
NZ718931A (en) 2022-10-28
WO2015059303A1 (en) 2015-04-30
HUE035875T2 (hu) 2018-06-28
US20180311291A1 (en) 2018-11-01
ZA201603646B (en) 2017-09-27
US9987314B2 (en) 2018-06-05
NO3021859T3 (es) 2018-04-28
CN114457044A (zh) 2022-05-10
KR20160067184A (ko) 2016-06-13
BR112016008973A2 (pt) 2017-09-19
US20160331793A1 (en) 2016-11-17
LT3021859T (lt) 2018-06-11
CA2927968C (en) 2023-02-21
MX2016005170A (es) 2017-02-02
AU2014338864A8 (en) 2018-08-23
MX373835B (es) 2020-07-08
AU2014338864A1 (en) 2016-05-05
TR201802728T4 (tr) 2018-03-21
EA201690545A1 (ru) 2016-09-30
PE20160951A1 (es) 2016-09-17
SG11201602887QA (en) 2016-05-30
EP3021859A1 (en) 2016-05-25
CN108064159A (zh) 2018-05-22

Similar Documents

Publication Publication Date Title
ES2661132T3 (es) Adenovirus oncolíticos armados con genes heterólogos
Liu et al. The IGF2 intronic miR-483 selectively enhances transcription from IGF2 fetal promoters and enhances tumorigenesis
AU2017239633B2 (en) Adenoviral assembly method
CY1122833T1 (el) Ογκολυτικος αδενοϊος που κωδικοποιει μια πρωτεϊνη β7
CR8794A (es) Adenovirus quimericos para uso en el tratamiento del cancer
JP2013509168A5 (es)
US12233096B2 (en) Recombinant replication competent viruses comprising a coding region for glycogen synthase kinase-3 (GSK3) and methods of killing aberrant cells
Chen et al. Gadd45a is a heterochromatin relaxer that enhances iPS cell generation
JP2017501695A5 (es)
Yoo et al. Tumor suppression by apoptotic and anti‐angiogenic effects of mortalin‐targeting adeno‐oncolytic virus
Ikushima et al. An Id‐like molecule, HHM, is a synexpression group‐restricted regulator of TGF‐β signalling
BR112021017853A2 (pt) Vetores de dna não virais e usos dos mesmos para expressar terapêuticas de fviii
Suzuki et al. Preferable sites and orientations of transgene inserted in the adenovirus vector genome: The E3 site may be unfavorable for transgene position
Raki et al. Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients
Kang et al. Establishment of a mouse melanoma model system for the efficient infection and replication of human adenovirus type 5-based oncolytic virus
Wei et al. Dissecting the roles of E1A and E1B in adenoviral replication and RCAd-enhanced RDAd transduction efficacy on tumor cells
Javan et al. Constructing a novel hypoxia-inducible bidirectional shRNA expression vector for simultaneous gene silencing in colorectal cancer gene therapy
CN102108356B (zh) 新颖启动子及包含其之病毒载体
RU2011129900A (ru) Вектор с регулируемым невирусным промотором для трансгенного введения в клетки и ткани млекопитающих
ZA201808215B (en) Drought resistance multigene construct
Liu et al. A novel E1B-55kD-deleted oncolytic adenovirus carrying mutant KRAS-regulated hdm2 transgene exerts specific antitumor efficacy on colorectal cancer cells
Chen et al. Activity and tumor specificity of human heparanase gene core promoter
EA201890595A1 (ru) Онколитический аденовирус, кодирующий белок b7
RU2012103637A (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДА pAd-OK, КОДИРУЮЩАЯ БЕЛКИ ОСТ4 И KLF4 ЧЕЛОВЕКА, ЯВЛЯЮЩАЯСЯ ОСНОВОЙ ДЛЯ ПОЛУЧЕНИЯ ВИРУЛЕНТНЫХ АДЕНОВИРУСОВ, ПРЕДНАЗНАЧЕННЫХ ДЛЯ ПОЛУЧЕНИЯ ИНДУЦИРОВАННЫХ ПЛЮРИПОТЕНТНЫХ СТВОЛОВЫХ КЛЕТОК ЧЕЛОВЕКА
US20110105595A1 (en) Novel promoter and viral vector containing the same